Medication info
Kvarban Tablets 10/80mg

Kvarban Tablets 10/80mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletValsartan›80mg / 1 tablet
Manufacturer / importer
Pharmgen Science Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202003922 · Approved 2020.05.27

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis, cardiovascular risk, and mortality risk
Who takes it
Adults · Children
Adult dose
This medication is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take this medication at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with this medication at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with this medication at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with this medication at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with this medication at 40 mg once daily; the dose should not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medication orally twice daily, and it may be increased to 80 mg or 160 mg per dose. When coadministering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple coadministration of this medication with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medication twice daily. Thereafter, over several weeks, increase the dose according to the patient's tolerability, giving 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medication. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If administering 80 mg or more daily, when increasing the dose, consider whether the benefits of treatment outweigh the risks. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this medication, patients should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medication at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medication (a combination product containing the same amount of each active ingredient) for convenience.
Child dose
Pediatric essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. Pediatric heart failure: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Pharmgen Science Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis, cardiovascular risk, and mortality risk

  • Essential hypertension
  • heart failure
  • ACE inhibitor intolerance heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
View approved original text

This medication is used for patients who require simultaneous treatment with Valsartan and Rosuvastatin. Valsartan helps to reduce the risk of death in patients with hypertension, heart failure, and those with impaired cardiac function after myocardial infarction. It can be particularly used in heart failure patients who have side effects from ACE inhibitors. Rosuvastatin is primarily used as an adjunct treatment when dietary measures alone are not sufficient for patients with hypercholesterolemia and hyperlipidemia, and it is also effective for patients with homozygous familial hypercholesterolemia. This medication also helps slow the progression of atherosclerosis and contribute to reducing the risk of cardiovascular diseases and strokes, myocardial infarctions, and after vascular interventions. Therefore, it is used to improve the prevention and treatment of cardiovascular diseases.

How to take

Adult dose

This medication is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take this medication at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with this medication at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with this medication at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with this medication at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with this medication at 40 mg once daily; the dose should not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medication orally twice daily, and it may be increased to 80 mg or 160 mg per dose. When coadministering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple coadministration of this medication with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medication twice daily. Thereafter, over several weeks, increase the dose according to the patient's tolerability, giving 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medication. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If administering 80 mg or more daily, when increasing the dose, consider whether the benefits of treatment outweigh the risks. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this medication, patients should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medication at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medication (a combination product containing the same amount of each active ingredient) for convenience.

Child dose

Pediatric essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. Pediatric heart failure: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the 2nd and 3rd trimesters, so it should be discontinued immediately once pregnancy is confirmed. Women who are pregnant or may become pregnant and women who are breastfeeding should not take this medication, and appropriate contraception should be used if there is a possibility of pregnancy. It is recommended not to use this medication in patients with severely impaired liver function, liver cirrhosis, or bile duct obstruction. Patients with muscle disorders or hereditary angioedema, severe renal insufficiency, certain kidney diseases, and those allergic to any components of this medication should also avoid taking it. Caution is needed for elderly patients, patients with hyperkalemia, those with slightly impaired liver function, and patients with heart diseases, as dosage adjustments and regular checks may be necessary. This medication can cause serious muscle-related side effects such as myalgia or myopathy, and if symptoms such as muscle pain, weakness, or cramps occur, medical personnel should be notified immediately. It is important to regularly check liver function tests and blood tests for kidney function and potassium levels while taking this medication. This medication can interact with other drugs, so it is essential to inform medical personnel of any other medications being taken, especially when used in combination with potassium-sparing diuretics, potassium supplements, certain antibiotics, immunosuppressants, and fibrates. There is no specific antidote in case of overdose, so immediate medical attention should be sought for appropriate treatment, and observation may be necessary for symptoms of hypotension or decreased consciousness. The safety and efficacy for children and adolescents have not been established, so it is advisable not to use it in those under 18 years of age. During storage, keep it out of reach of children and do not transfer to other containers to maintain the quality of the medication. Avoid alcohol while taking this medication, and if there are any health issues related to the liver or kidneys, consult with medical personnel for careful management.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, asthenia, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum aminotransferase levels, increased serum creatinine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fracture, spinal fracture, fracture, skin tumor, 2nd degree atrioventricular block, vestibulitis, retinal detachment, unspecified skin neoplasm-like state, herpes zoster, intervertebral disc herniation, hemoptysis, sputum disease, bronchitis, paresthesia, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, increased blood pressure, worsening hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified skin inflammation, localized skin reactions, palpitations, angina exacerbation, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, dyspepsia, pharyngitis, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, kidney function impairment, hyperkalemia, drowsiness, atrial fibrillation, decreased appetite, malaise, vascular edema, erythema, pruritus, serum sickness, vasculitis, hepatitis, arrhythmia, intestinal vascular edema, interstitial pneumonia, hypoglycemia, shock, syncope, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin, edema, insomnia, erythema, decreased libido, dizziness, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscle weakness, oculobulbar weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a special container that protects it from light. Additionally, it is safe to store the medication at room temperature, between 1 to 30 degrees Celsius, avoiding excessively hot or cold conditions.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.